Latest News
Karyopharm Therapeutics Inc.
- Karyopharm stock: November 2 is the estimated results date for Karyopharm stock
- Karyopharm Therapeutics Extends Forbearance Period to November 1, 2026
- Investing.com lists USD 7.25 target for Karyopharm stock
- Karyopharm stock approaches November 2 earnings with USD 33.54 million forecast
- Six analysts give Karyopharm stock a USD 11.50 consensus target
- Karyopharm Therapeutics extends forbearance period to Oct. 22 under indenture agreement
- Two Acorn funds account for one manager’s reported stake in Karyopharm (KPTI).
- Karyopharm Therapeutics (KPTI) Slips 7.45% to $0.80, Testing Support Near $0.76 - Opening Range Breakout
- Karyopharm Therapeutics (KPTI) Slips 7.45% to $0.80, Testing Support Near $0.76 - Exhaustion Gap
- A tax-related sale: Karyopharm (KPTI) accounting chief sells 378 shares at $1.19 each.
- Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Two partnerships report Karyopharm (KPTI) shares; their manager has shared voting power.
Headlines from the last 30 days, linking to the original publishers. See all market news →